AI Healthcare Breakthroughs Tracker: OpenAI, Anthropic, Google DeepMind and the AI Science Labs

OpenAI, Anthropic, Google DeepMind and a new class of AI science labs are racing to change how medicines are found and how patients are diagnosed. This tracker logs every health and drug discovery move we can verify, back to each company’s first one, and grades every result by how far it has actually been proven. Last updated October 28, 2026.

What Counts as a Frontier AI Lab in Healthcare?

We sort companies by what they build, not by how much they raised. A frontier lab trains its own general foundation model and points it at health. An AI science lab trains its own models built for biology or medicine and usually runs experiments and drug programs. Everyone else builds on those models, and that is a separate category.

Tier	What they build	Examples	What their news usually means
Tier 1: Frontier labs	General foundation models (GPT, Claude, Gemini, Llama, Microsoft’s MAI and research models) applied to health and science	OpenAI, Anthropic, Google DeepMind, Microsoft, Meta	New tools, partnerships and acquisitions; results are often benchmarks or company reports
Tier 2: AI science labs	Their own biology or chemistry models, usually paired with lab experiments and drug programs	Isomorphic Labs, Insilico Medicine, Generate Biomedicines, Recursion, Xaira Therapeutics, Chai Discovery	Molecules, preclinical data and clinical trials; this is where drug breakthroughs will be tested
Tier 3: Health AI applications	Products built on other companies’ models	Most AI scribes, symptom chatbots and care navigation tools	Workflow and access changes; judged on clinical and operational outcomes

The lines blur at the edges, and we say so on each page. Anthropic now runs its own wet lab and drug programs, which looks like tier 2 work. Microsoft trains its own biomedical models but also distributes OpenAI models it did not train, which behaves like tier 3. Meta’s health impact runs mainly through open models that other groups build on.

How We Grade Each Breakthrough

Every result gets one evidence level and the stage it reached. A deal, hire or funding round is logged but never graded as a result, because money is not evidence that something works. The scale is fixed and applies to every company the same way, including the ones whose tools we use.

Evidence level	What it means
1. Announced	A goal or plan, with no data shared
2. Company-reported	Data shared by the company in a blog post, technical report, press release or preprint that has not been peer reviewed
3. Peer-reviewed	Published in a peer-reviewed journal
4. Independently replicated	Confirmed by a group with no tie to the company
5. Tested in people	Results from a human clinical trial or a prospective study in patients

Stages run from research tool, target discovery and molecule design through preclinical work and Phase 1, 2 and 3 trials to approval. Clinical AI tools are marked Clinical care, and work on documents, regulatory filings or manufacturing is marked Operations. For the biggest announcements we also publish a progress check that compares the headline with the evidence, and we add a HYPE Index score only when we have read the full study.

Latest Moves: The 2026 Running Log

This log lists every verified 2026 move on our company pages, newest first. Each company’s page carries its full history back to its first health move. Studies by outside groups that only use a company’s open models are left to the company pages.

Date	Company	Move	Evidence level	Source
Oct 22, 2026	Microsoft	Microsoft AI paper in Science: a system that simulates a panel of physicians reached 83.2% accuracy on hard published cases versus 36.1% for generalist physicians, in a benchmark setting	Peer-reviewed, Clinical care	PMID 42912144
Oct 2026	Anthropic	Acquired Mithril, a one-person biotech, and started its own drug programs	Not a result	The Next Web
Oct 2026	Anthropic	Published a report on early drug development work with six partner companies; coverage cites an 89% cut in drug development paperwork time and cancer-fighting cells that worked longer in lab tests	Company-reported, Molecule design	Anthropic
Oct 2026	Anthropic	Claude produced 35,000 antibody designs in one month aimed at food allergy targets	Company-reported, Molecule design	Interesting Engineering
Oct 2026	Google DeepMind	AMIE tested with 98 real urgent primary care patients before their visits at Beth Israel Deaconess (Lancet)	Tested in people, Clinical care	PMID 42849491
Oct 2026	Isomorphic Labs	Reported to be in funding talks at a valuation of at least $40 billion; terms not final	Not a result	Bloomberg
Oct 2026	OpenAI	Acquired Orchestra Bio, a startup that puts AI agents into drug programs; the agents are being folded into GPT-Rosalind	Not a result	Crypto Briefing
Sep 23, 2026	Anthropic	Announced an enzyme system resembling CRISPR that it says Claude found after scanning about 200,000 enzymes	Company-reported, Research tool	TechCrunch
Sep 18, 2026	Anthropic	Confirmed a Bay Area wet lab that runs biology experiments	Not a result	TechCrunch
Sep 16, 2026	Anthropic	Partnered with Novo Nordisk to speed up drug development with Claude	Not a result	BNN Bloomberg
Sep 2026	Insilico Medicine	Nature Biotechnology analysis of serum from the rentosertib Phase 2a trial: six proteomic aging clocks all predicted lower biological age in treated arms	Peer-reviewed, Phase 2 (exploratory biomarker analysis)	PMID 42706338
Aug 19, 2026	Microsoft	AdventHealth review of DAX Copilot across 210 providers: active note time fell 26.2% per appointment	Peer-reviewed, Operations	PMID 42618038
Aug 2026	Anthropic	Reported that Claude designed protein binders against 14 of 15 targets that passed lab tests, and released the dataset	Company-reported, Molecule design	Anthropic
Jul 14, 2026	Generate Biomedicines	First-in-human trial of GB-0669, an AI-optimized antibody against a conserved part of the SARS-CoV-2 spike, published: 51 healthy adults, well tolerated, half-life of 54 days	Tested in people, Phase 1	PMID 42446369
Jul 13, 2026	Chai Discovery	Raised a $400M Series C at a $3.8B valuation; coverage named Lilly, Novartis and Pfizer as users of its models	Not a result	Business Wire
Jul 6, 2026	Xaira Therapeutics	Hired Ian McCaffery as SVP for translational science	Not a result	Business Wire via Enid News
Jun 30, 2026	Anthropic	Released Claude Science, a product aimed at researchers and the pharma industry	Not a result	STAT
Jun 26, 2026	OpenAI	Randomized trial of a GPT-4o decision support tool in 16 Kenyan primary care clinics, run by outside researchers with Penda Health: better notes, no drop in 14-day treatment failure	Tested in people, Clinical care	PMID 42362867
Jun 25, 2026	OpenAI	OpenAI and Boston Children’s Hospital researchers report 18 new rare disease diagnoses in 376 unsolved cases using an AI-assisted genome reanalysis workflow	Peer-reviewed, Clinical care	PMID 42529462
Jun 2, 2026	Microsoft	Mayo Clinic and Microsoft announce a collaboration to develop a frontier AI model for healthcare	Not a result	Microsoft Source
Jun 2026	Anthropic, Google DeepMind	AlphaFold co-creator and Nobel laureate John Jumper said he would leave Google DeepMind for Anthropic	Not a result	Bloomberg Government
Jun 2026	Google DeepMind	AMIE disease management study in Nature: a Gemini-grounded AMIE was non-inferior to 21 primary care physicians on management reasoning across 100 simulated multivisit cases	Peer-reviewed, Clinical care	PMID 42310463
May 20, 2026	Anthropic	Signed a strategic agreement with Bristol Myers Squibb to make Claude Enterprise a shared platform across its global operations	Not a result	BioSpace
May 2026	Google DeepMind	AI co-scientist published in Nature; drug repurposing ideas for leukemia confirmed in lab tests	Peer-reviewed, Preclinical	PMID 42156544
May 2026	Isomorphic Labs	Raises a $2.1 billion Series B to scale its AI drug design engine	Not a result	Isomorphic Labs
Apr 30, 2026	OpenAI	Harvard, Beth Israel Deaconess and Stanford study in Science: an OpenAI model outperformed physician baselines on hard diagnostic cases and emergency room second opinions	Peer-reviewed, Clinical care	PMID 42060751
Apr 16, 2026	OpenAI	Launched GPT-Rosalind, a model for life sciences research and drug discovery	Not a result	Axios
Apr 14, 2026	OpenAI	Novo Nordisk partnership to use OpenAI models in drug discovery and operations	Not a result	BioPharm International
Apr 2026	Anthropic	Added Novartis CEO Vas Narasimhan to its board	Not a result	Anthropic
Apr 2026	Anthropic	Acquired Coefficient Bio, a stealth AI startup, for a reported $400 million	Not a result	Fierce Biotech
Apr 2026	Insilico Medicine	Formed a Longevity Board chaired by Eli Lilly’s Andrew Adams, with Nobel laureate Michael Levitt among its members	Not a result	Insilico via AlphaGalileo
Apr 2026	OpenAI	HealthBench Professional: OpenAI says ChatGPT for Clinicians outperformed physicians on clinical tasks, even when the physicians had unlimited time and web access	Company-reported, Clinical care	arXiv
Mar 25, 2026	Xaira Therapeutics	Hired Rachel Lane as SVP business development and operations	Not a result	Business Wire
Mar 17, 2026	Xaira Therapeutics	Launched X-Cell, its first virtual cell model, described in coverage as the largest to date	Company-reported, Research tool	Business Wire via Joplin Globe
Mar 2026	Microsoft	Microsoft Research publishes a report on how people use Copilot for health	Not a result	Microsoft Research
Jan 31, 2026	Microsoft	Independent nursing study: the agent-based MAI-DxO system outscored ChatGPT-4 and 110 dialysis nurses on four hemodialysis scenarios	Peer-reviewed, Clinical care	PMID 41620749
Jan 27, 2026	OpenAI	Released Prism, an AI workspace for scientific research and writing	Not a result	Engadget
Jan 12, 2026	OpenAI	Acquired Torch, a medical records startup, for a reported $100 million, to power ChatGPT Health	Not a result	SiliconANGLE
Jan 11, 2026	Anthropic	Launched Claude for Healthcare and partnered with HealthEx to let users connect medical records	Not a result	Fortune
Jan 8, 2026	Chai Discovery	Collaboration with Eli Lilly to speed biologics discovery with custom AI models	Not a result	Business Wire
Jan 8, 2026	OpenAI	Launched ChatGPT Health, a health space that can connect medical records and wellness apps through b.well	Not a result	HLTH
Jan 8, 2026	OpenAI	Announced a ChatGPT tool for doctors	Not a result	Axios
Jan 7, 2026	Anthropic	Genmab partnered with Anthropic to use agentic AI in research and development	Not a result	Business Wire
Jan 2026	Google DeepMind	AlphaGenome DNA model published in Nature	Peer-reviewed, Research tool	PMID 41606153
Jan 2026	Isomorphic Labs	Reuters reports that Isomorphic has delayed its first clinical trial timeline	Announced, Preclinical	Reuters via WHBL
2026	Generate Biomedicines	Initial public offering on Nasdaq raised $400 million at $16 per share	Not a result	pharmaphorum

For deal terms and what each 2026 acquisition adds, see our 2026 AI lab biotech deal tracker.

Milestones Before 2026

The race did not start with ChatGPT. Microsoft Research applied machine learning to immune data from HIV patients in 2006, Recursion-affiliated scientists ran a machine-learning drug screen in 2014, and Google DeepMind and Insilico Medicine made their first health moves in 2016. This table lists each company’s first move and its most important results before 2026, newest first; each company page links the source for every row.

Date	Milestone	Evidence level
Dec 15, 2025	Chai Discovery, described by TechCrunch as OpenAI-backed, raises a $130 million Series B at a $1.3 billion valuation	Not a result
Dec 1, 2025	Generate Biomedicines announces global Phase 3 studies of GB-0895, a long-acting antibody for severe asthma engineered with AI	Not a result
Dec 2025	Recursion reports Phase 1b/2 TUPELO results for REC-4881, a MEK inhibitor, in familial adenomatous polyposis, describing reductions in polyp burden	Company-reported, Phase 2 (Phase 1b/2 trial)
Nov 26, 2025	UCLA randomized trial of 238 physicians: Microsoft‘s DAX Copilot did not significantly cut time in notes; survey measures suggested less burnout	Tested in people, Operations
Oct 20, 2025	Anthropic launches Claude for Life Sciences, its first dedicated life sciences product	Not a result
Jul 2025	OpenAI and Penda Health report 16% fewer diagnostic errors with an AI Consult copilot across about 40,000 patient visits	Company-reported, Clinical care
Jun 30, 2025	Chai Discovery announces Chai-2 for zero-shot antibody design	Company-reported, Molecule design
Jun 17, 2025	Xaira Therapeutics releases X-Atlas/Orion, a genome-wide Perturb-seq dataset of about 8 million cells	Company-reported, Research tool
Jun 2025	Insilico Medicine‘s rentosertib Phase 2a results published in Nature Medicine: 71 patients with idiopathic pulmonary fibrosis, 12 weeks, safety as the primary endpoint	Tested in people, Phase 2
May 2025	Recursion deprioritizes three clinical programs after a data review, months after its Exscientia merger	Not a result
Apr 2025	Google DeepMind‘s AMIE diagnostic dialogue and differential diagnosis papers published in Nature	Peer-reviewed, Clinical care
Nov 2024	Recursion completes its merger with Exscientia	Not a result
Oct 2024	Demis Hassabis and John Jumper of Google DeepMind share the Nobel Prize in Chemistry for protein structure prediction	Independently replicated, Research tool
Sep 2024	Chai Discovery comes out of stealth with a seed round of about $30 million backed by OpenAI and Thrive Capital	Not a result
Jun 2024	Recursion publishes Phase 1 results for REC-994 in 84 healthy volunteers: well tolerated	Tested in people, Phase 1
May 2024	AlphaFold 3, built by Google DeepMind and Isomorphic Labs, published in Nature	Peer-reviewed, Research tool
Apr 23, 2024	Xaira Therapeutics launches with $1 billion in funding commitments	Not a result
Mar 2024	Insilico Medicine reports in Nature Biotechnology that its AI nominated TNIK as a fibrosis target and generated the molecule now called rentosertib, with a Phase 1 in 78 healthy participants	Tested in people, Phase 1
Feb 6, 2024	The OpenAI Startup Fund co-leads a $70 million round in Ambience Healthcare, the earliest dated health move by OpenAI we could source	Not a result
Nov 2023	Generate Biomedicines publishes its Chroma protein design model in Nature	Peer-reviewed, Research tool
Jan 2023	A prospective study of 170 patients finds AI-accelerated knee MRI from the Meta and NYU fastMRI work diagnostically equivalent to the standard scan	Tested in people, Clinical care
Mar 7, 2022	Microsoft completes its $19.7 billion acquisition of Nuance, maker of the DAX documentation software	Not a result
Mar 2022	Google Health diabetic eye screening AI tested prospectively in Thailand’s national program (see Google DeepMind)	Tested in people, Clinical care
Nov 2021	Alphabet launches Isomorphic Labs to turn AlphaFold into drug discovery	Not a result
Mar 31, 2021	Flagship Pioneering names Mike Nally to lead Generate Biomedicines, its earliest dated move we could source	Not a result
Nov 2020	AlphaFold 2 from Google DeepMind tops the CASP14 blind protein structure assessment; the Nature paper follows in July 2021	Independently replicated, Research tool
Aug 20, 2018	Facebook AI Research and NYU School of Medicine launch fastMRI, Meta‘s first medical research move	Not a result
Nov 2017	Facebook begins using AI to spot posts that may signal suicide risk, the first health move by Meta we could source	Not a result
Nov 2016	DeepMind Health partners with the Royal Free London NHS trust on the Streams app; the UK data regulator ruled in July 2017 that the trial did not comply with data protection law	Not a result
May 2016	Insilico Medicine publishes deep neural networks that estimate age from a routine blood test	Peer-reviewed, Research tool
Dec 2014	Recursion-affiliated scientists use a machine-learning image screen of 2,100 known drugs to find two that cut lesion burden in a mouse model of cerebral cavernous malformation	Peer-reviewed, Preclinical
Jul 15, 2006	A Microsoft Research machine learning model of immune peptide binding is applied to HIV data from 246 patients, the earliest Microsoft health or biology move we could source	Peer-reviewed, Research tool

Where Each Lab Stands: The Scorecard

The furthest result tells you more than the funding total. This table shows each company’s best-proven health result so far, as graded on its own page.

Company	Tier	Own models	Own wet lab	First health move	Furthest result so far
Google DeepMind	1	Yes (Gemini, Gemma, AlphaFold, AMIE, AlphaGenome and others)	Not confirmed	2016	Tested in people, Clinical care (AMIE and diabetic eye screening studies); Independently replicated, Research tool (AlphaFold)
OpenAI	1	Yes (GPT series, GPT-Rosalind, GPT-4b micro)	None found	February 2024	Tested in people, Clinical care (randomized trial by outside researchers; primary outcome not met)
Microsoft	1	Yes (Prov-GigaPath, BiomedParse, BioEmu, TamGen and diagnostic research); also distributes OpenAI models	Not confirmed	July 2006	Tested in people, Operations (DAX Copilot randomized trials)
Meta	1	Yes (Llama; ESM protein models until the team left)	No	November 2017	Tested in people, Clinical care (fastMRI with NYU)
Anthropic	1	Yes (general-purpose Claude models; no biology-specific model found)	Yes	October 2025	Company-reported, Molecule design
Insilico Medicine	2	Yes (PandaOmics, Chemistry42, inClinico, nach0)	Yes	May 2016	Tested in people, Phase 2 (rentosertib Phase 2a, peer-reviewed; primary endpoint safety)
Recursion	2	Yes (OpenPhenom-S/16; Boltz-2 with MIT)	Yes	December 2014	Tested in people, Phase 1 (REC-994, peer-reviewed); its Phase 2 data for REC-994 and REC-4881 are company-reported
Generate Biomedicines	2	Yes (Chroma)	Yes	March 2021	Tested in people, Phase 1 (GB-0669, peer-reviewed); GB-0895 is in Phase 3 with no results yet
Isomorphic Labs	2	Yes (AlphaFold 3 with Google DeepMind; Isomorphic Labs Drug Design Engine)	Not confirmed	November 2021	Peer-reviewed, Research tool (AlphaFold 3)
Chai Discovery	2	Yes (Chai-1, Chai-2)	Not disclosed	September 2024	Company-reported, Molecule design (Chai-2); Peer-reviewed, Research tool (outside tests of Chai-1)
Xaira Therapeutics	2	Yes (X-Cell)	Yes	April 2024	Company-reported, Research tool

“First health move” is the earliest dated health or biology move we could source, not necessarily the company’s founding date.

Tier 1: How the Frontier Labs Are Moving Into Health

The frontier labs are taking three different routes: build products, buy pieces of the drug business, or spin out a drug company.

Google DeepMind has the best-proven result. AlphaFold changed structural biology, and its AMIE diagnostic system was tested with 98 patients before urgent primary care visits at Beth Israel Deaconess in a 2026 Lancet feasibility study (PMID 42849491). Its drug work runs through its sister company Isomorphic Labs.

OpenAI moved fast in 2026 with ChatGPT Health, GPT-Rosalind, and the Torch and Orchestra Bio acquisitions, and TechCrunch describes Chai Discovery as OpenAI-backed. Its strongest test so far was run by outside researchers with Penda Health, with no OpenAI authors: a cluster-randomized trial of a GPT-4o decision support tool in 16 Kenyan primary care clinics improved notes but did not change 14-day treatment failure (PMID 42362867).

Anthropic is integrating vertically. It confirmed its own Bay Area wet lab in September 2026, bought Coefficient Bio and Mithril, and started its own drug programs, alongside deals with Genmab, Bristol Myers Squibb and Novo Nordisk. Its results, including Claude-designed protein binders and an enzyme system resembling CRISPR, are company-reported, and we found no peer-reviewed paper or human trial for an Anthropic health or drug result. Our progress check on its partner results grades each one.

Microsoft owns Nuance, maker of DAX Copilot, and trains its own biomedical models. It published its sequential diagnosis study in Science on October 22, 2026: 83.2% accuracy on hard published cases versus 36.1% for generalist physicians, in a benchmark on past cases (PMID 42912144). Its furthest result is in documentation: randomized trials of DAX Copilot found no significant cut in note-writing time, though clinicians reported a better experience. See our progress check on the MAI-DxO study.

Meta has a health record made mostly of open research that others build on: open Llama models, the fastMRI work with NYU, and the ESM protein models, whose team left to found EvolutionaryScale.

Tier 2: The AI Science Labs Where Drugs Get Tested

Tier 2 is where AI-designed molecules meet real biology and, eventually, patients.

Insilico Medicine holds the most advanced published drug result among the labs we track. In the rentosertib Phase 2a trial, 71 patients with idiopathic pulmonary fibrosis were treated for 12 weeks at sites in China; the primary endpoint was safety, and the lung function signal at the highest dose needs larger and longer trials (PMID 40461817).

Generate Biomedicines published the first-in-human trial of GB-0669, an AI-optimized antibody, in 2026 (PMID 42446369), and has GB-0895 in Phase 3. Recursion has company-reported Phase 2 data for REC-994 and REC-4881, but its best-proven human result is still a peer-reviewed Phase 1 safety study, and it deprioritized three clinical programs in 2025. Isomorphic Labs raised $2.1 billion in May 2026, but Reuters reported in January 2026 that its first clinical trials were delayed, and we found no dosed patient as of October 28, 2026.

Chai Discovery and Xaira Therapeutics are earlier. Each trains its own models and has raised large sums, but neither has a disclosed drug candidate in a clinical trial.

Tier 3: Why Health AI Apps Are a Separate Category

Most health tech companies using AI do not train foundation models. They build scribes, chatbots, triage and navigation tools on top of models from tier 1 labs. Their success depends on clinical and operational outcomes, such as time saved, errors avoided and patients helped, rather than on scientific discovery. We cover them in our wider AI in medicine reporting and do not list them in this tracker.

Also on Our Watch List

• Lila Sciences: a Flagship Pioneering company unveiled on March 10, 2025 with a $200 million seed round (SiliconANGLE), it has since raised a $350 million Series A that includes $115 million with backing from Nvidia’s venture arm (Fierce Biotech), at a valuation above $1.3 billion as Reuters reported in October 2025 (Yahoo Finance), and Bloomberg reported talks at an $8.5 billion valuation (Bloomberg). Its job listings point to protein engineering work (General Catalyst job board), but as of October 28, 2026 it has announced no drug candidate, pharma partner or health result. We will give it a full page when it names a biology program or publishes health data.
• EvolutionaryScale: founded by former Meta ESM researchers, it launched with a $142 million round in June 2024 (TechCrunch).
• Edison Scientific and Periodic Labs: AI scientist startups. FutureHouse spun out Edison Scientific and its Kosmos research agent in November 2025 (HPCwire), and Edison raised $70 million in December 2025 (SiliconANGLE). Former OpenAI and DeepMind researchers launched Periodic Labs with a $300 million seed round to automate science (TechCrunch).
• Nvidia: an investor across tier 2, including a $50 million investment in Recursion in 2023 (CNBC), Generate’s Series C (Business Wire) and Lila Sciences (Fierce Biotech).

How Far Has AI Drug Discovery Really Come?

AI-discovered drugs look better than average in early safety trials but not yet in efficacy trials. A 2024 analysis of AI-native biotech pipelines in Drug Discovery Today found AI-discovered molecules succeeded in Phase 1 80 to 90 percent of the time, above historical averages, but about 40 percent of the time in Phase 2, comparable to history and on a limited sample (PMID 38692505). The next two years of Phase 2 and Phase 3 readouts will show whether that gap closes. For the full picture, see where AI-designed drugs stand in human trials, our rentosertib verdict and why AI drug discovery is not one thing.

How This Tracker Is Kept Current

We review the log every week. Newsletters and headlines are treated as leads only; every entry is confirmed against the company’s own announcement, a named news report, PubMed or ClinicalTrials.gov before it is added. Evidence levels change when new evidence appears, and each change is noted on the company’s page.

Update log: October 28, 2026, tracker published with company pages for five frontier labs and six AI science labs, plus progress checks on Microsoft’s MAI-DxO study and Anthropic’s partner results. Lila Sciences moved to the watch list because it has no health result to grade yet.

What This Means for You

If you are a patient, nothing in this tracker changes what your doctor can prescribe today. The most advanced AI-discovered drugs are still in Phase 2 and Phase 3 trials. Clinical AI tools are reaching clinics faster, so ask whether a tool your care team uses was tested with patients like you, not only on past cases.

If you work in research or care, read every AI headline for two things: who produced the evidence and what stage it reached. A company report about early design work and a peer-reviewed trial in patients are not the same news, even when the headlines sound alike.

Compiled by Healthcare Discovery from company announcements, named news reports and PubMed. Every PMID on this page was checked against PubMed on October 28, 2026. Healthcare Discovery uses AI research tools from several companies on this page, including OpenAI, Anthropic and Google models; no company listed reviewed or paid for this page.

Sources

1. Jumper J, et al. Highly accurate protein structure prediction with AlphaFold. Nature, 2021. PMID 34265844
2. Xu Z, et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nature Medicine, 2025. PMID 40461817
3. Brodeur PG, et al. Conversational diagnostic artificial intelligence in ambulatory primary care: a prospective feasibility study. Lancet, 2026. PMID 42849491
4. Agweyu A, et al. Generative AI-enabled clinical decision support system in primary care: a pragmatic, cluster-randomized trial. Nature Medicine, 2026. PMID 42362867
5. Nori H, et al. Sequential diagnosis with language models. Science, 2026. PMID 42912144
6. Borriello F, et al. Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix. The Journal of Infectious Diseases, 2026. PMID 42446369
7. Kp Jayatunga M, et al. How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons. Drug Discovery Today, 2024. PMID 38692505
8. Nobel Prize. The Nobel Prize in Chemistry 2024 press release, October 2024. Nobel Prize
9. DeepMind. AlphaFold: a solution to a 50-year-old grand challenge in biology, November 2020. DeepMind
10. SiliconANGLE. Lila Sciences raises $200M to accelerate autonomous scientific research, March 2025. SiliconANGLE
11. Fierce Biotech. Lila Sciences adds $115M to Series A, bringing total haul to $350M and securing backing from Nvidia, October 2025. Fierce Biotech
12. Reuters via Yahoo Finance. Exclusive: AI lab Lila Sciences funding round, October 2025. Yahoo Finance
13. Bloomberg. Lila Sciences said in talks for funds at $8.5 billion valuation. Bloomberg
14. General Catalyst job board. Lila Sciences: ML Scientist I/II, AI for protein engineering. General Catalyst
15. TechCrunch. EvolutionaryScale, backed by Amazon and Nvidia, raises $142M for protein-generating AI, June 2024. TechCrunch
16. HPCwire. FutureHouse spins out Edison Scientific, launches Kosmos AI for research, November 2025. HPCwire
17. SiliconANGLE. Edison Scientific raises $70M to build autonomous AI scientists, December 2025. SiliconANGLE
18. TechCrunch. Former OpenAI and DeepMind researchers raise whopping $300M seed to automate science, September 2025. TechCrunch
19. CNBC. Nvidia invests in biotech company Recursion for AI drug discovery, July 2023. CNBC
20. Business Wire. Generate Biomedicines announces close of $273M Series C financing, September 2023. Business Wire
21. Every entry in the running log links its own source; each company page lists its full sources.